Evidence map›Paper›PMID 38888232›Full record

ArticleNano letters2024

Lung-Specific mRNA Delivery Enabled by Sulfonium Lipid Nanoparticles.

David O Popoola, Zhi Cao, Yuqin Men, Xinyuan Li, Mariano Viapiano, Stephan Wilkens, Juntao Luo, Yong Teng, Qinghe Meng, Yamin Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nano letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Decoding Undesirable Inflammatory Responses of Nucleic Acid-Delivering Lipid Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

David O PopoolaDepartment of Pharmacology, State University of New York, Upstate Medical University, Syracuse, New York 13210, United States.
Zhi CaoDepartment of Pharmacology, State University of New York, Upstate Medical University, Syracuse, New York 13210, United States.
Yuqin MenDepartment of Pharmacology, State University of New York, Upstate Medical University, Syracuse, New York 13210, United States.
Xinyuan LiDepartment of Pharmacology, State University of New York, Upstate Medical University, Syracuse, New York 13210, United States.
Mariano ViapianoDepartment of Neuroscience and Physiology, State University of New York, Upstate Medical University, Syracuse, New York 13210, United States.
Stephan WilkensDepartment of Biochemistry and Molecular Biology, State University of New York, Upstate Medical University, Syracuse, New York 13210, United States.
Juntao LuoDepartment of Pharmacology, State University of New York, Upstate Medical University, Syracuse, New York 13210, United States.ORCID 0000-0002-3538-9453
Yong TengDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, United States.
Qinghe MengDepartment of Surgery, State University of New York, Upstate Medical University, Syracuse, New York 13210, United States.
Yamin LiDepartment of Pharmacology, State University of New York, Upstate Medical University, Syracuse, New York 13210, United States.ORCID 0000-0002-5535-1807

Funding

Development of Sulfonium- and Phosphonium-based Cationic Lipid Materials for mRNA DeliveryR03EB032579 · NIBIB · UPSTATE MEDICAL UNIVERSITY · PI LI, YAMIN · 2022 to 2023
$163k
NIBIB NIH HHS R03 EB032579
6 · The paper itself

Abstract

Among various mRNA carrier systems, lipid nanoparticles (LNPs) stand out as the most clinically advanced. While current clinical trials of mRNA/LNP therapeutics mainly address liver diseases, the potential of mRNA therapy extends far beyond─yet to be unraveled. To fully unlock the promises of mRNA therapy, there is an urgent need to develop safe and effective LNP systems that can target extrahepatic organs. Here, we report on the development of sulfonium lipid nanoparticles (sLNPs) for systemic mRNA delivery to the lungs. sLNP effectively and specifically delivered mRNA to the lungs following intravenous administration in mice. No evidence of lung and systemic inflammation or toxicity in major organs was induced by sLNP. Our findings demonstrated that the newly developed lung-specific sLNP platform is both safe and efficacious. It holds great promise for advancing the development of new mRNA-based therapies for the treatment of lung-associated diseases and conditions.

Indexed as

LipidsLungNanoparticlesRNA, MessengerAnimalsGene Transfer TechniquesHumansLiposomesMiceSulfonium CompoundsLipid NanoparticlesLipidsLiposomesRNA, MessengerSulfonium Compoundsgenome engineeringlung targetingmRNA deliverypulmonary endotheliumSulfonium lipid nanoparticle

Identifiers

PMID38888232
PMCPMC12013526

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.